News | October 06, 2024
Briefs: Aurobindo Pharma and Lupin
USFDA completes PAI of Lupin’s biotech facility in Pune
USFDA completes PAI of Lupin’s biotech facility in Pune
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
The transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines (BSV) by Mankind Pharma
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
